文献速递泌尿生殖与妇科肿瘤放疗

前列腺癌局灶高剂量率近距离放疗推量联合立体定向放疗(fBTsRT):一项II期随机对照试验

Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial.
PubMed 文献 · Radiat Oncol · 2022-12-09

本研究为II期随机对照试验,计划纳入150例中高危前列腺癌患者,1:1随机比较局灶高剂量率近距离放疗推量联合立体定向放疗(fBTsRT)与标准治疗(全前列腺高剂量率近距离放疗推量联合放疗)对泌尿功能生活质量的影响,主要终点为EPIC-26量表在1年和2年时泌尿功能最小重要下降的患者比例。

要点

  • fBTsRT组接受局灶高剂量率近距离放疗推量13-15 Gy单次,随后立体定向放疗36.25-40 Gy分5次,隔日照射。
  • 主要终点为EPIC-26量表评估的1年和2年泌尿功能最小重要下降(MID)患者比例,以判断fBTsRT是否优于标准治疗。
  • 纳入标准要求计划接受标准治疗高剂量率近距离放疗推量且GTV占前列腺体积<50%的中高危前列腺癌患者。

核心结论

  • 本研究旨在确定fBTsRT这一新方法能否在不损害肿瘤控制的前提下改善生活质量,并值得进一步评估。

研究设计与样本

  • II期随机对照试验,采用队列多重随机设计,计划纳入150例中高危前列腺癌患者,1:1随机分组。
  • 纳入标准为计划接受标准治疗高剂量率近距离放疗推量且GTV占前列腺体积<50%的患者。
  • 随机选中的患者接受实验性治疗fBTsRT:局灶高剂量率近距离放疗推量13-15 Gy单次,随后立体定向放疗36.25-40 Gy分5次(± elective盆腔25 Gy),隔日照射。
  • 主要终点为EPIC-26量表评估的1年和2年泌尿功能最小重要下降(MID)患者比例。
  • 次要终点包括CTCAE评估的毒性发生率和无失败生存结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with a higher burden of localized prostate cancer, radiation dose escalation with brachytherapy boosts have improved cancer control outcomes at the cost of urinary toxicity. We hypothesize that a focal approach to brachytherapy boosts targeting only grossly visualized tumor volumes (GTV) combined with stereotactic radiotherapy will improve quality of life (QoL) outcomes without compromising cancer control. METHODS: 150 patients with intermediate or high-risk prostate cancer will be enrolled and randomized 1:1 in a cohort multiple randomized clinical trial phase 2 design. Patients are eligible if planned for standard-of-care (SOC) high dose rate (HDR) brachytherapy boost to radiotherapy (RT) with GTVs encompassing < 50% of the prostate gland. Those randomly selected will be offered the experimental treatment, consisting of focal HDR brachytherapy boost (fBT) of 13-15 Gy in 1 fraction followed by stereotactic radiotherapy (sRT) 36.25-40 Gy in 5 fractions to the prostate (+/- 25 Gy to the elective pelvis) delivered every other day. The primary endpoint is to determine if fBTsRT is superior to SOC by having fewer patients experience a minimally important decline (MID) in urinary function as measured by EPIC-26 at 1 and 2 years. Secondary endpoints include rates of toxicity measured by Common Terminology Criteria for Adverse Events (CTCAE), and failure-free survival outcomes. DISCUSSION: This study will determine whether a novel approach for the treatment of localized prostate cancer, fBTsRT, improves QoL and merits further evaluation. Trial registration This trial was prospectively registered in ClinicalTrials.gov as NCT04100174 as a companion to registry NCT03378856 on September 24, 2019.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Belliveau C, Barkati M, Delouya G, et al. Focal HDR brachytherapy boost to stereotactic radiotherapy (fBTsRT) for prostate cancer: a phase II randomized controlled trial. Radiat Oncol. 2022. PMID: 36494834. doi:10.1186/s13014-022-02173-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。